Welcome to the 3rd TRP Supply Chain & Manufacturing Summit
In the high-stakes world of radiopharmaceuticals, the industry is just beginning to realize the full potential of this targeted therapy modality. A surge of capital flowing into the field is signalling not only robust investment, but a shared urgency to strengthen supply pipelines and scale clinical manufacturing capacity.
- Lantheus restructures to sharpen radiopharma focus: acquired CDMO Evergreen Theragnostics for $1B to scale therapeutic manufacturing (January 2025), while divesting its legacy SPECT business to SHINE Technologies to streamline operations in PET diagnostics and next-gen therapeutics (May 2025).
- Philocem AG licenses OncoACP3 to RayzeBio (a Bristol Myers Squibb company) in a deal worth up to $1.35B (June 2025).
- Ratio Therapeutics teams with Wasatch Group to develop 65,000-square-foot radiopharmaceutical research and manufacturing facility, expanding production capacity and infrastructure (May 2025).
Alongside this growth, however, the challenge of consistently delivering safe, scalable, and timely radiopharmaceuticals to patients remains.
The 3rd Targeted Radiopharmaceuticals (TRP) Supply Chain & Manufacturing Summit returns to Boston this September to help you strengthen infrastructure, streamline workflows, and future-proof roles in a rapidly evolving and expanding radiopharmaceutical landscape.
Explore how to optimize production capabilities and build a resilient, efficient supply chain by delving into critical topics such as strategic isotope selection, manufacturing scale-up, supplier quality control, regulatory transparency, and last-mile supply networks.
As the only industry-dedicated forum uniting 70+ of the leading C-suite and senior decision-makers in the radiopharmaceutical CMC, regulatory, QC, and supply chain fields, gain exclusive technical and logistical insights from the likes of from AstraZeneca, Novartis, Clarity Pharmaceuticals, Ratio Therapeutics, ImaginAB, and more.
Why Attend?
1
2
3
4
5
Mitigate drug loss and delivery delays by refining end-to-end supply chain strategies and last-mile coordination with clinical sites, ensuring patients receive critical therapies on time.
Advance regulatory readiness through enhanced CMC practices and improved quality system alignment with evolving global standards, reducing compliance risks and accelerating approvals.
Strengthen clinical continuity by proactively navigating isotope sourcing challenges and building resilient supplier relationships, minimizing disruptions in clinical and commercial production.
Stay ahead of industry shifts by benchmarking against innovative technologies, digital tools, and automation driving scalable manufacturing, gaining competitive advantage and operational efficiency.
Future-proof development programs by understanding infrastructure demands and operational models needed to support both clinical and commercial-stage radiopharmaceuticals, enabling sustainable growth and market readiness.
Your Expert Speakers Include:
2025 Partners
